^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

SAR445514

i
Other names: SAR445514, IPH6401, SAR'514
Associations
Trials
Company:
Innate, Sanofi
Drug class:
NK cell stimulant, BCMA inhibitor
Related drugs:
Associations
Trials
18d
Trial primary completion date
|
SAR445514
10ms
A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA) (clinicaltrials.gov)
P1/2, N=101, Recruiting, Sanofi | Trial completion date: Mar 2027 --> Jun 2027 | Trial primary completion date: Jan 2026 --> Apr 2026
Trial completion date • Trial primary completion date
|
SAR445514
over1year
The novel trifunctional anti-BCMA NK cell engager SAR’514 has potent in-vitro, in-vivo and ex-vivo anti-myeloma effect through dual NK cell engagement (AACR 2023)
Importantly, SAR’514 exhibits ex vivo efficacy using bone marrow mononuclear cells (BMMC) from MM patients in an autologous setting showing an active and efficient primary MM cell killing against MM cells from patients that have failed diverse therapies, including standard of care treatments. In summary, these results demonstrate the efficacy of SAR’514 for controlling MM tumors in vivo and ex vivo, and provide consistent support for its clinical development.
Preclinical • IO biomarker
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • FCGR3A (Fc Fragment Of IgG Receptor IIIa) • IL1B (Interleukin 1, beta)
|
SAR445514
2years
The Novel Trifunctional Anti-BCMA NK Cell Engager SAR'514 Has Potent in-Vitro and in-Vivo Anti-Myeloma Effect through Dual NK Cell Engagement (ASH 2022)
As compared to the control group in which only 20% of mice survived with a median survival day of 44.5 days, SAR'514 induced a significant mouse survival from 0.5 mg/kg to 5 mg/kg with an overall survival of 90% and a median survival day over 90 days. In summary, these results demonstrate the efficacy of SAR'514 for controlling MM tumors in vivo and provide consistent support for its clinical development.
Preclinical • IO biomarker
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • FCGR3A (Fc Fragment Of IgG Receptor IIIa) • IL1B (Interleukin 1, beta)
|
SAR445514